Role of MicroRNAs from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Overview

Journal Semin Hematol

Specialty Hematology

Date 2011 Jan 15

PMID 21232657

Citations 10

Authors

Katherine R Calvo

Ola Landgren

Aldo M Roccaro

Irene M Ghobrial

Affiliations

Soon will be listed here.

Abstract

microRNAs (miRNAs) are increasingly recognized as significant players in oncogenesis and tumor biology through post-transcriptional gene regulation impacting broad pathways of proliferation, differentiation, apoptosis, metastasis, and cell survival. Recent studies have found abnormal expression of miRNAs in multiple myeloma (MM). Currently, the precise role of these miRNAs in the biology of MM remains to be elucidated, although they are predicted to be involved in plasma cell proliferation, survival, homing, or in MM cell interactions with the bone marrow microenvironment. Furthermore, a limited number of studies focusing on MM precursor disease (monoclonal gammopathy of undetermined significance [MGUS]) reveal significant differences in miRNA profiles between MGUS and normal plasma cells. Interestingly, several of the microRNAs differentially expressed in MGUS also show aberrant expression in MM, suggesting a role in early myelomagenesis. miRNA profiles can discriminate molecular subtypes of MM that are defined based on gene expression profiling (GEP) and cytogenetic abnormalities, demonstrating the potential diagnostic/prognostic utility of miRNA profiling for subclassification of MM. Given the relative stability of miRNA and ability to isolate miRNA from routine clinical specimens, miRNA analysis promises to facilitate personalized diagnostics and therapies, and to provide insights into the biology of early myelomagenesis.

Citing Articles

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.

Vlachova M, Gregorova J, Vychytilova-Faltejskova P, Gablo N, Radova L, Pospisilova L Int J Mol Sci. 2022; 23(23).

PMID: 36499093 PMC: 9741227. DOI: 10.3390/ijms232314765.

MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease.

Desantis V, Solimando A, Saltarella I, Sacco A, Giustini V, Bento M Cancers (Basel). 2021; 13(15).

PMID: 34359551 PMC: 8344971. DOI: 10.3390/cancers13153650.

Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance.

Wang W, Shim Y, Michalek J, Barber E, Saleh L, Choi B J Toxicol Environ Health A. 2020; 83(7):269-278.

PMID: 32285757 PMC: 7908056. DOI: 10.1080/15287394.2020.1749919.

Circulating microRNAs and Their Role in Multiple Myeloma.

Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A Noncoding RNA. 2019; 5(2).

PMID: 31052608 PMC: 6631121. DOI: 10.3390/ncrna5020037.

Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.

Wang W, Corrigan-Cummins M, Barber E, Saleh L, Zingone A, Ghafoor A J Mol Diagn. 2015; 17(6):669-78.

PMID: 26433312 PMC: 4630165. DOI: 10.1016/j.jmoldx.2015.06.006.

References

Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S . An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics. 2008; 1:37. PMC: 2531129. DOI: 10.1186/1755-8794-1-37. View

Jenner M, Leone P, Walker B, Ross F, Johnson D, Gonzalez D . Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007; 110(9):3291-300. DOI: 10.1182/blood-2007-02-075069. View

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

Griffiths-Jones S, Saini H, van Dongen S, Enright A . miRBase: tools for microRNA genomics. Nucleic Acids Res. 2007; 36(Database issue):D154-8. PMC: 2238936. DOI: 10.1093/nar/gkm952. View

Jongen-Lavrencic M, Sun S, Dijkstra M, Valk P, Lowenberg B . MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008; 111(10):5078-85. DOI: 10.1182/blood-2008-01-133355. View

Corthals S, Jongen-Lavrencic M, de Knegt Y, Peeters J, Beverloo H, Lokhorst H . Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res. 2009; 34(5):677-81. DOI: 10.1016/j.leukres.2009.10.026. View

Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S . Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007; 7:36. PMC: 1914054. DOI: 10.1186/1472-6750-7-36. View

Fonseca R, Blood E, Rue M, Harrington D, Oken M, Kyle R . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003; 101(11):4569-75. DOI: 10.1182/blood-2002-10-3017. View

Wang K, Li P . Foxo3a regulates apoptosis by negatively targeting miR-21. J Biol Chem. 2010; 285(22):16958-66. PMC: 2878079. DOI: 10.1074/jbc.M109.093005. View

10.

Miranda K, Huynh T, Tay Y, Ang Y, Tam W, Thomson A . A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006; 126(6):1203-17. DOI: 10.1016/j.cell.2006.07.031. View

11.

Zhang J, Jima D, Jacobs C, Fischer R, Gottwein E, Huang G . Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009; 113(19):4586-94. PMC: 2680365. DOI: 10.1182/blood-2008-09-178186. View

12.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

13.

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

14.

Medina P, Slack F . microRNAs and cancer: an overview. Cell Cycle. 2008; 7(16):2485-92. DOI: 10.4161/cc.7.16.6453. View

15.

Chen Y, Lavelle D, DESIMONE J, Uddin S, Platanias L, Hankewych M . Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). Blood. 1999; 94(1):251-9. View

16.

Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P . Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica. 2009; 95(2):260-9. PMC: 2817029. DOI: 10.3324/haematol.2009.012088. View

17.

Visone R, Croce C . MiRNAs and cancer. Am J Pathol. 2009; 174(4):1131-8. PMC: 2671346. DOI: 10.2353/ajpath.2009.080794. View

18.

Eis P, Tam W, Sun L, Chadburn A, Li Z, Gomez M . Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005; 102(10):3627-32. PMC: 552785. DOI: 10.1073/pnas.0500613102. View

19.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

20.

Li S, Tang P, Lin W . Intronic microRNA: discovery and biological implications. DNA Cell Biol. 2007; 26(4):195-207. DOI: 10.1089/dna.2006.0558. View